Clinical Trial Update: Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study evaluating activity and safety of ezutromid (SMT C1100) in boys with Duchenne Muscular Dystrophy was terminated; results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ezutromid (SMT C1100)

Snippet

Sponsor: Summit Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED | Results posted: 2020-01-02